VC-backed Sorbent Therapeutics expands board of directors

Sorbent Therapeutics, a Sunnyvale, Calif.-based biopharmaceutical firm focused on treating cardiovascular and renal diseases, has added Jay Shepard and William D. Waddill to its board of directors. Shepard is an executive partner at Sofinnova Ventures while Waddill is the senior vice president and chief financial officer at Calithera Biosciences. Sorbent’s backers include CMEA Capital, ARCH Venture Partners, Sofinnova Ventures, AgeChem and Novartis Venture Funds.

VC-backed Syros Pharmaceuticals hires new CFO

Syros Pharmaceuticals said Tuesday that it has hired Jorge Conde as chief financial officer and chief product officer. Previously, Conde was the co-founder and CFO of Knome. Based in Watertown, Mass., Syros is focused on treating cancer and other diseases. It is backed by Flagship Ventures and ARCH Venture Partners.

VC-backed Siluria Technologies promotes two

Siluria Technologies has promoted Rahul Iyer to vice president of corporate development and Gary Koehler to vice president of operations. Siluria is a company that converts natural gas into chemicals and fuels. It is backed by ARCH Venture Partners, The Wellcome Trust, Alloy Ventures, Kleiner Perkins Caufield & Byers, Bright Capital, Altitude Life Science Ventures, Lux Capital and Vulcan Capital.

Twist Bioscience nabs $26 mln Series B

Twist Bioscience said Tuesday that it has raised $26 million in Series B financing. Tao Invest led the round with participation from other investors that included ARCH Venture Partners and Paladin Capital Group. Also, the company has received a $5.1 million contract from DARPA. Based in San Francisco, Twist Bioscience produces synthetic DNA.

Sorbent Therapeutics closes first tranche in $15 mln Series D

Sorbent Therapeutics, a Sunnyvale, Calif.-based biopharmaceutical firm focused on treating cardiovascular and renal diseases, has closed a $6.5 million tranche in a $15 million Series D financing. The investors were CMEA Capital, ARCH Venture Partners, Sofinnova Ventures, AgeChem and Novartis Venture Funds.

128 Views

ARCH raising $250 mln for new venture fund

ARCH Venture Partners is raising an eighth venture fund with a smaller target of $250 million, according to a filing with the Securities and Exchange Commission. The filing for ARCH Venture Fund VIII lists six managing directors: Keith Crandell, Robert Nelsen, Clinton Bybee, Mark McDonnell, Kristina Burow and Paul Thurk. Managing Director Steven Gillis is not listed.

SAGE Therapeutics nabs $38 mln Series C funds

SAGE Therapeutics has closed $38 million in Series C financing. Investors included OrbiMed Advisors, EcoR1 Capital Management, Foresite Capital Management, Third Rock Ventures and ARCH Venture Partners. Based in Cambridge, Mass., SAGE Therapeutics is a biopharmaceutical company focused on treating orphan central nervous system disorders.

VC-backed Achaogen debuts IPO

Achaogen has launched its IPO after pricing its 6 million shares at $12 per share. The stock began trading Wednesday on the NASDAQ under the ticker symbol “AKAO.” Credit Suisse Securities and Cowen and Company are the lead underwriters. Based in South San Francisco, Achaogen is a biopharmaceutical company focused on developing antibiotics to treat bacterial infections. Its backers include 5AM Ventures, ARCH Venture Partners, Venrock, Versant Ventures, Frazier Healthcare Ventures, Domain Associates and Alta Partners.

SAGE Therapeutics secures $20m Series B financing

Biopharmaceutical company SAGE Therapeutics has secured a $20 million Series B financing from investors ARCH Venture Partners and Third Rock Ventures, bringing the total raised to $57.8 million since launch in 2011. The Series B financing will accelerate clinical and preclinical efforts to continue to advance SAGE’s pipeline programs in CNS disorders.

Siluria Technologies Appoints to Board

Siluria Technologies has appointed Karl Kurz to the company’s board of directors. Siluria is a company that converts natural gas into chemicals and fuels. It is backed by ARCH Venture Partners, The Wellcome Trust, Alloy Ventures, Kleiner Perkins Caufield & Byers, Bright Capital, Altitude Life Science Ventures, Lux Capital and Vulcan Capital.

Siluria Raises $30M From Bright, Vulcan, Kleiner, ARCH, Alloy, Others

Siluria Technologies said it closed a $30 million Series C financing led by new investors Bright Capital and Vulcan Capital and joined by existing investors ARCH Venture Partners, The Wellcome Trust, Alloy Ventures, Kleiner Perkins Caufield and Byers, Lux Capital, Altitude Life Science Ventures and Presidio Ventures. The company is developing a technology to convert […]

W Fund Officially Launches to Invest in Washington-Based Start-ups

Seattle-based W Fund, a $20 million, university-focused  fund that officially closed on May 31, officially launched today, according to its managing directors. The fund aims to back startups spun out of the University of Washington and other state research institution and its decisions will be made by an investment committee that Tom Alberg and Greg […]

Fate Therapeutics Appoints chairman and interim CEO

San Diego headquartered biotech company Fate Therapeutics has appointed William H. Rastetter as chairman and interim CEO. Rastetter is also a partner in venture capital firm Venrock. Fate Therapeutics has secured venture backing from OVP Venture Partners, Astellas Venture Management, Genzyme Ventures, ARCH Venture Partners, Polaris Venture Partners and Venrock. PRESS RELEASE Fate Therapeutics, Inc. […]

PEHUB Community

Join the 12500 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

PE HUB News Briefs

RSS Feed Widget

Marketplace

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget